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Abstract: 
 
In the field of natural products chemistry, a common question pertains to the authenticity of an 
isolated compound, i.e. are the interesting side chains biosynthesized naturally or an artefact of 
the isolation/purification processes? The droplet-liquid microjunction-surface sampling probe 
(droplet-LMJ-SSP) coupled to a hyphenated system (UPLC-UV-HRESIMS) empowers the 
analysis of natural product sources in situ, providing data on the biosynthetic timing and spatial 
distribution of secondary metabolites. In this study the droplet-LMJ-SSP was utilized to validate 
the authenticity of two new peptaibols (2 and 3) as biosynthesized secondary metabolites, even 
though both of them had structural features that could be perceived as artefacts. Compounds 2 
and 3 were isolated from the scaled up fermentation of Trichoderma arundinaceum (strain 
MSX70741), along with a new member of the trichobrevin BIII complex (1), and four known 
compounds (4–7). The structures of the isolates were established using a set of spectroscopic and 
spectrometric methods, and their absolute configurations were determined by Marfey's analysis. 
The cytotoxic activity of compounds 1, 3, 4 and 6 was evaluated against a panel of cancer cell 
lines, where cytotoxic activity in the single digit μM range was observed. 
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In the field of natural products chemistry, a common question pertains to the authenticity of an isolated
compound, i.e. are the interesting side chains biosynthesized naturally or an artefact of the isolation/
purification processes? The droplet-liquid microjunction-surface sampling probe (droplet-LMJ-SSP)
coupled to a hyphenated system (UPLC-UV-HRESIMS) empowers the analysis of natural product sources
in situ, providing data on the biosynthetic timing and spatial distribution of secondary metabolites. In this
study the droplet-LMJ-SSP was utilized to validate the authenticity of two new peptaibols (2 and 3) as
biosynthesized secondary metabolites, even though both of them had structural features that could be
perceived as artefacts. Compounds 2 and 3 were isolated from the scaled up fermentation of
Trichoderma arundinaceum (strain MSX70741), along with a new member of the trichobrevin BIII
complex (1), and four known compounds (4–7). The structures of the isolates were established using
a set of spectroscopic and spectrometric methods, and their absolute configurations were determined
by Marfey's analysis. The cytotoxic activity of compounds 1, 3, 4 and 6 was evaluated against a panel of
cancer cell lines, where cytotoxic activity in the single digit mM range was observed.Introduction
Fungi are a rich source of bioactive secondary metabolites with
therapeutic activities.1–3 The recent estimates for fungal biodi-
versity range from 2.2 to 3.8 million species;4 however, only
a fraction of these fungi (135 000 species) have been taxo-
nomically characterized and an even smaller percentage
examined chemically.5 Thus, our understanding of the chemical
diversity and pharmacological applications of most fungi is still
quite limited. Amongst the well-studied fungi, Trichoderma
species are known for their ability to produce bioactive
secondary metabolites, including polyketides, alkaloids, terpe-
noids, non-ribosomally biosynthesized peptides (NRPs), and
metabolites of mixed biogenesis.6–8 Between the NRPs, peptai-
bols represent the largest group, with more than 1000
compounds reported to date.9 These molecules, typically
composed of 5–20 amino acid residues, are characterized by
a high content of a-aminoisobutyric acid (Aib), an acylated N-stry, University of North Carolina at
-mail: nicholas_oberlies.uncg.edu
Developmental Biology, University of
8, USA
ESI) available: 1D and 2D NMR data for
alysis for compounds 1–3. Marfey's
ed NMR data for compounds 2–4. See
hemistry 2017terminus, and a C-terminus that may consist of a free or
methoxy substituted 2-amino alcohol, amine, amide, free
amino acid or sugar alcohol.10–14
When working on a well-studied structural class, it is rela-
tively easy to pose questions about the biosynthetic authenticity
of a new analogue. Artefacts of the isolation process are a well
accepted problem.15–17 In addition to adding some confusion to
the natural products literature, the biosynthetic authenticity of
a compound can be important when considering how certain
compounds either support or refute a biosynthetic pathway. In
this context, there is value to the development of strategies to
either authenticate or invalidate isolated compounds as true
secondary metabolites.
Herein, we communicate the application of the recently
described droplet-liquid microjunction-surface sampling
probe (droplet-LMJ-SSP), which was coupled to a UPLC chro-
matographic system and paired with both UV and HRESIMS
detectors,18 to validate the biosynthetic authenticity of fungal
secondary metabolites. The droplet-LMJ-SSP is a manually
controlled surface sampling tool that performs a micro-
extraction on the culture surface. The droplet-LMJ-SSP has
been used in various types of analysis of fungal cultures,
including the in situ scouting and identication of peptai-
bols,19 dereplication18 and mapping of the spatial and
temporal distribution of fungal metabolites,20,21 and to
monitor the biosynthesis of targeted non-natural natural
products.22RSC Adv., 2017, 7, 45733–45741 | 45733
Fig. 1 Structures of compound 1–3.
RSC Advances Paper
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View Article OnlineAs part of our ongoing research to discover new anticancer
leads from lamentous fungi,23–27 Trichoderma arundinaceum
strain MSX70741,10 a well-known peptaibols producer from the
Mycosynthetix library (with more than 55 000 fungal acces-
sions28) was reinvestigated. Consequently, the scaled up culture
of strain MSX70741 on rice led to the isolation of three new
peptaibols (1–3, Fig. 1), together with the four known
compounds alamethicin F50 (4), alamethicin II (5), atroviridin J
(6), and trichobranchin D-I (7).10 The structures of the isolates
were established using a set of spectroscopic (1D and 2D NMR)
and spectrometric (HRESIMS/MSn) techniques. The absolute
congurations of these isolates were determined by Marfey's
analysis.10,29 The cytotoxic activities of compounds 1, 3, 4 and 6
were evaluated in an MTT assay against a panel of human
cancer cell lines: HCT 116 (colorectal carcinoma), DLD-1,
HT-29, and SW948 (colorectal adenocarcinomas), Hep-G2, and
Huh-7 (hepatocellular carcinomas), and HeLa (adenocarci-
noma).30 The evaluated compounds displayed cytotoxic activi-
ties with IC50 values in the single digit mM range. Finally, in situ
analysis of the cultures of MSX70741 cultured on potato-
dextrose-agar (PDA) conrmed the authenticity of the
compounds as natural products, discarding the possibility of
artefacts of the isolation/purication process.Fig. 2 Positive HRESIMS of compound 1. (A) Full scan showing in
source fragmentation, (B–D) HRESIMS/MSn of fragments b5
+, y6
+ and
y2
+, respectively.Results and discussion
Structure elucidation
Previous studies on Trichoderma arundinaceum strain
MSX70741 stimulated this project,10 largely to amplify the
supply of key peptaibols for pharmacological assays, as will be
reported in the future. Thus, to increase the supply of those
peptaibols, four large scale cultures were set up, extracted with
1 : 1 CHCl3–MeOH and partitioned with 4 : 1 : 5 CHCl3/MeOH/
H2O.25,26,31 The pooled organic soluble extract was then frac-
tionated using normal phase ash chromatography to yield ve
fractions. Further purication of the fraction that eluted with
100% MeOH employing reverse phase ash chromatography,
followed by preparative and semi-preparative HPLC, led to the
isolation of three new metabolites (trichobrevin BIII-D, pre-
alamethicin F50, and Glu(OMe)18-alamethicin F50, 1–3,
respectively) (Fig. 1), along with multi-mg to hundred-mg45734 | RSC Adv., 2017, 7, 45733–45741samples of the known peptaibols, alamethicin F50 (4), alame-
thicin II (5), atroviridin J (6), and trichobranchin D-I (7).
Compounds 1 and 7 were isolated as white amorphous
powders, and their molecular formulae were determined to be
C56H99N11O13 and C55H97N11O13 on the basis of HRESIMS data
(m/z) 1134.7496 [M + H]+, and 1120.7343 [M + H]+, respectively
(calc. for C56H100N11O13 and C55H98N11O13). In combination
with NMR studies, these data indicated 13 degrees of unsatu-
ration for both compounds. Literature searches based on
molecular formulae and exact masses in the Dictionary of
Natural Products and Peptaibiotics databases indicated that
compound 7 was the known peptaibol trichobranchin D-I,
previously isolated by Ayers et al.,10 while 1 was closely related
to the trichobrevin subclass of peptaibols. The amino acid
sequence of compound 1 was established on the basis of
HRESIMS/MS data. For example, the full scan spectrum showed
characteristic ions at m/z 1134.7506 [M + H]+, 920.5819 (b9
+, N-
terminal fragment), 512.3082 (b5
+), 623.4493 (y6
+, C-terminal
fragment) and 215.1754 (y2
+), all fragments generated by
cleavage of the labile bonds between Aib5–Pro6 and Aib9–Pro10
(Fig. 2).28 Further fragmentation of the ion b5
+ generated a series
of b+ ions (Ac-b1
+–b4
+; m/z ¼ 128.0709, 215.1014, 314.1720, and
427.2575, respectively), providing information about the
successive losses of Aib,5 Lxx4 (Leu or Ile), Vxx3 (Val or Iva), and
Ser2 (Fig. 2). HRESIMS/MS of the C-terminal fragment y6
+ yiel-
ded a series of ions corresponding to the loss of the fragment y2
+
(m/z ¼ 409.2804), Aib9 (m/z ¼ 324.2305), and Lxx8 (m/z ¼
211.1445), the last accounting for the molecular formula
C11H19N2O2 and corresponding with a b fragment constitutedThis journal is © The Royal Society of Chemistry 2017
Paper RSC Advances
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View Article Onlineby Pro and Lxx (Fig. 2). Finally, MS3 of fragment y2
+ conrmed
the presence of Lxxol (Leuol or Ileol) as the C-terminal amino
acid by generation of the y1
+ fragment at m/z ¼ 118.1228,
consistent with the formula C6H16NO. In view of the data ob-
tained from mass spectrometry, the putative amino acid
sequence of compound 1 was Ac–Aib1–Ser2–Vxx3–Lxx4–Aib5–
Pro6–Lxx7–Lxx8–Aib9–Pro10–Lxxol.11
Based upon a detailed search in the Peptaibiotics Database
(https://peptaibiotics-database.boku.ac.at), which contains
1350 entries, including over 980 peptaibols, the putative amino
acid arrangement of compound 1 resembled the structure of the
trichobrevin BIII complex, a family of three compounds iden-
tied by HPLC-Ion-Trap-ESIMS in the extract of some strains ofTable 1 NMR spectroscopic data for compound 1 (700 and 175 MHz, 1H
Position dC Type dH, mult. (J in Hz)
Ac
C]O 171.0 C
CH3 23.0 CH3 1.91, s
Aib1
C]O 176.1 C
a 55.7 C
b1 23.8 CH3 1.34, s
b2 26.3 CH3 1.36, s
NH 8.77, s
Ser2
C]O 171.2 C
a 58.3 CH 3.991
b 60.5 CH2 3.66–3.75, m
NH 8.42, d (4.3)
OH 5.34, brs
Val3
C]O 171.5 C
a 60.4 CH 3.86, dd (7.5, 7.4)
b 29.0 CH 2.13, dq-like (13.7, 6.9)
g1 19.1 CH3 0.89, d (6.8)
g1 18.9 CH3 0.93, d (6.8)
NH 7.68, d (7.4)
Ile4
C]O 172.5 C
a 57.6 CH 4.12, t (7.8)
b 35.5 CH 1.89, m
g1a 24.6 CH2 1.24, m
g1b 1.41, m
d 10.5 CH3 0.76, t (7.4)
g2 15.5 CH3 0.84, d (6.9)
NH 7.30, d (8.5)
Aib5
C]O 173.0 C
a 56.1 C
b1 25.5 CH3 1.38, s
b2 23.0 CH3 1.45, s
NH 7.97, s
Pro6
C]O 173.3 C
a 63.3 CH 4.20, dd (8.1, 7.6)
b1 28.6 CH2 1.59
a
b2 2.24, m
g 25.7 CH2 1.86
a
d1 48.5 CH2 3.39, dt (11.7, 7.9)
a Overlapping signals; chemical shis were determined from 1H–13C HSQ
This journal is © The Royal Society of Chemistry 2017Trichoderma brevicompactum.32 Members of the trichobrevin
BIII complex share the amino acid sequence Ac–Aib1–Ser2–Vxx3–
Lxx4–Aib5–Pro6–Lxx7–Lxx8–Aib9–Pro10–Lxxol;11 however, in the
study published by Degenkolb in 2006, the unambiguous
identity of Vxx,3 Lxx,4 Lxx,7 Lxx,8 and Lxxol11 was not estab-
lished.32 In this communication we report the isolation and
structural elucidation of a member of this family, which was
assigned the trivial name trichobrevin BIII-D (1). The planar
structure of compound 1 was established based on exhaustive
interpretation of 1D and 2D NMR data, and the absolute
conguration of the individual amino acids was established
from the complete acid hydrolysis and chemical derivatization
with Marfey's reagent, followed by UPLC-UV analysis.and 13C, respectively) in DMSO-d6
Position dC Type dH, mult. (J in Hz)
d2 3.65
a
Leu7
C]O 172.6 C
a 53.1 CH 3.96a
b1 38.7 CH2 1.47
a
b2 1.85
a
g 24.4 CH 1.72a
d1 20.8 CH3 0.83, d (6.6)
d2 23.0 CH3 0.92, d (6.6)
NH 7.53, d (7.9)
Leu8
C]O 172.2 C
a 50.6 CH 4.29a
b 39.6a CH2 1.55
a
g 24.1 CH 1.59a
d1 20.3 CH3 0.74, d (6.4)
d2 22.8 CH3 0.79, d (6.4)
NH 7.16, d (9.1)
Aib9
C]O 171.5 C
a 55.7 C
b1 25.5 CH3 1.32, s
b2 23.8 CH3 1.36, s
NH 7.52, s
Pro10
C]O 171.1 C
a 62.2 CH 4.24, dd (8.3, 6.4)
b1 28.9 CH2 1.64, m
b2 2.08, m
g 25.4 CH2 1.76, m
d1 48.0 CH2 3.22, dt (11.3, 7.2)
d2 3.65, m
Ileol11
a 54.5 CH 3.66a
b 34.9 CH 1.59a
g1a 23.9 CH2 0.99, ddd (13.5, 9.2, 7.0)
g1b 1.46
a
d 11.6 CH3 0.83, t (7.5)
g2 16.0 CH3 0.81, d (7.0)
b01 61.2 CH2 3.36, dd (11.3, 6.7)
b02 3.45
a
NH 7.02, d (9.4)
OH 3.98a
C correlations.
RSC Adv., 2017, 7, 45733–45741 | 45735
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View Article OnlineIn brief, the 1H-NMR of 1 recorded in DMSO-d6 exhibited
resonances for nine exchangeable protons between dH 7.02–
8.77 ppm (showed by recording the spectra in MeOH-d3),
signals among dH 3.22–4.29 ppm belonging to the a-H's, six
singlet signals among dH 1.32–1.45 ppm, attributed to Aib,1 Aib5
and Aib,9 several doublets ascribed to Val,3 Leu,7 Leu,8 and two
triplets at dH 0.76 (J ¼ 7.4 Hz), and dH 0.83 (J ¼ 7.5 Hz), which
were unambiguously assigned to Ile4 and Ileol,11 respectively. In
addition, the presence of a sharp singlet at dH 1.91 ppm in the
1H NMR spectrum of 1 conrmed the presence of an acetylated
N-terminal residue (Table 1). The 13C-NMR spectrum displayed
11 signals between dC 171.0–176.1 ppm assigned to amide
carbonyl groups, 15 signals ranging dC 48–70 ppm, and several
resonances in the alkyl region.28,33,34 Interpretation of the
2D-NMR data (1H–1H TOCSY, 1H–1H COSY, 1H–13C HSQC and
1H–13C HMBC), in particular TOCSY, permitted the assembly of
each amino acid through the total spin correlations observed.
NOESY correlations of the amide NH's protons with their cor-
responding neighbouring amino acids, along with HMBC cross
peaks of the amide protons through 2JCH with their i-1 carbonyl
group, and aC, and 3JCH of the aH's with the i carbonyl group
(Fig. 3), conrmed the sequence of 1 as shown.34
The absolute conguration of the individual amino acids in
compound 1 was established using a 10 min Marfey's-UPLC-UV
method.29 The general procedure started with the acid hydro-
lysis of 1, followed by derivatization of the hydrolysate under
alkaline conditions with Na-(2,4-dinitro-5-uorophenyl)-L-ala-
ninamide (L-FDAA, Marfey's reagent), followed by UPLC-UV
analysis at 340 nm. Finally, the UPLC retention times of the
derivatized amino acids in 1 were compared with those of
derivatized L and D standards for each amino acid (Fig. S7†).10
Thus the unambiguous structure of compound 1 was assigned
as Ac–Aib1-L-Ser2-L-Val3-L-Ile4–Aib5-L-Pro6-L-Leu7-L-Leu8–Aib9-L-
Pro10-L-Ileol11 and given the trivial name trichobrevin BIII-D. In
all of our previous studies on peptaibols, the amino acids were
L,10,28 as is typical for this particular class of compounds.
Compound 2 was isolated as a white powder with a molec-
ular formula of C78H132N20O22 as evidenced by HRESIMS data
and analysis of the 1H, 13C, and edited-HSQC NMR data (Table
S1, Fig. S10, S11 and S14†), revealing an index of hydrogen
deciency of 23. The positive full scan MS spectrum of 2 dis-
played four intense peaks at m/z 1701.9910 ([M + H]+, calc. for
C78H133N20O22, 1701.9897), 1189.6946 (b13
+, fragment),
851.4989 ([M + 2H]2+), and 513.3032 (y5
+, fragment) (Fig. S8†).
The composition and absolute conguration of the amino acids
was conrmed on the basis of MS2 and Marfey's analysis (Fig. 4Fig. 3 Selected TOCSY, HMBC and NOESY correlations observed for
compound 1.
45736 | RSC Adv., 2017, 7, 45733–45741and S9†). Thus, the residues were conrmed to be Aib (8), L-Ala
(2), L-Pro (2), L-Val (2), L-Gln (2), and L-Leu (1). By acid hydrolysis,
the Gln residues in the molecule were converted into Glu,35
however, losses of 146.069 and 128.056 a.m.u. in the MS2
spectrum of fragments y5
+ (m/z 513.3032) and b7
+ (m/z
665.3597), respectively, supported the presence of L-Gln
(Fig. S9†).11 Analysis of 1D and 2D NMR data revealed that all
the amino acids and connections were the same as those in
alamethicin F50 (4). The main differences in 2 compared to 4
were the absence of two signals around at dH 6.63 and 7.34,
assigned to the NH2 group of Gln19 in 4, as well as the lack of
resonances attributed to the aromatic ring of the Pheol20 moiety
(Table S1†). Therefore, the structure of compound 2 was
established as Ac–Aib1–Pro2–Aib3–Ala4–Aib5–Ala6–Gln7–Aib8–
Val9–Aib10–Gly11–Leu12–Aib13–Pro14–Val15–Aib16–Aib17–Gln,18 and
assigned the trivial name of prealamethicin F50 (2), since it had
the same amino acid sequence minus two C-terminal residues,
indicating its close relationship to 4.
Compound 3 was also isolated as a white powder, and its
molecular formula was established as C93H152N22O25 on the
basis of HRESIMS data, which displayed a protonated molec-
ular ion at m/z 1978.1385 [M + H]+ (calc. for C93H153N22O25, m/z
1978.1371). In source fragmentation of compound 3 generated
peaks corresponding to the fragments b13
+ and y7
+ at m/z
1189.6943 and 789.4504, respectively, along with the [M + 2H]2+
ion at m/z 989.5727. MS2 of the fragment b13
+ supported the
sequence Ac–Aib1–Pro2–Aib3–Ala4–Aib5–Ala6–Gln7–Aib8–Val9–
Aib10–Gly11–Leu12–Aib.13 MS2 of fragment y7
+ showed the loss of
m/z 279.15987 (C14H21N3O3), accounting for Gln19 and Pheol.20
Further fragmentation of the ion at m/z 510.2917 gave origin
to a peak at m/z 367.2338, indicating the loss of m/z 143.0581
(C6H9NO3
+), matching accurately for glutamic acid d-methyl
ester. Thus, MS2 analysis allowed the elucidation of the
sequence Pro14–Val15–Aib16–Aib17–Glu–OMe18–Gln19–Pheol20
(Fig. S16 and S17†). 1H, 13C, and 2D-NMR data of compound 3
were similar to those recorded for alamethicin F50 (4) (Table
S1†), the main differences being the absence of protons attrib-
uted to the NH2 group of Gln18 (Table S1†), which were replaced
by a methoxy group at dH/dC (3.57/51.2), showing strong HMBC
correlations with the d carbon of glutamic acid at dC 172.8,
supporting the presence of glutamic acid d-methyl ester. As
expected, Marfey's analysis of compound 3 was the same as thatFig. 4 Marfey's analysis of compound 2.
This journal is © The Royal Society of Chemistry 2017
Paper RSC Advances
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View Article Onlinefor alamethicin F50 (4), allowing the establishment of the
absolute conguration of the individual amino acids in
compound 3 as L-Pro, L-Ala, L-Gln, L-Val, L-Leu, L-Glu, and
L-Pheol (Fig. S24†). Thus, compound 3 was characterized as the
d-methyl ester of Glu18 in alamethicin F50, and assigned the
name Glu(OMe)18-alamethicin F50 (3). This compound was
previously obtained via semisynthesis in 1977 by Pandey et al.,
in a study focused on the structure elucidation of alamethicin I
and II, however it is the rst report as natural product.36
The occurrence of methyl esters of glutamic acid in peptaibols
is rare. For example, of the over 1350 peptaibiotics reported in the
Peptaibiotics Database, there are just four examples of this
subclass of analogues, TA1896, TA1924, TA1910 and TA1924a, all
of which are peptaibols with 19 amino acid residues isolated
from Trichoderma atroviride by Panizel et al. in 2013.37 Thus, the
isolation and characterization of compound 3 represents the
second report of glutamic acid methyl ester containing peptai-
bols isolated from nature, and the rst belonging to the alame-
thicin class, the most extensively studied peptaibol.38
In situ chemical analysis
A question that may arise in natural products research pertains
to the authenticity of a compound. Is the isolated compoundFig. 5 In situ analysis of Trichoderma arundinaceum strain MSX70741 gro
(droplet-LMJ-SSP) coupled to a hyphenated system (UPLC-UV/HRESIM
(maroon), 2 (green) and 3 (blue). (B) Full-scan HRESIMS for compounds 1 (to
analysis of Trichoderma arundinaceum strain MSX70741 (grey); extracted io
andm/z 789.44 (3, blue) matching retention times for compounds 1–3. (D
5.78 and 6.95minmatched the retention times and in source fragmentatio
in source fragments boxed inmaroon), and 3 (bottom, in source fragments
the identification of compounds 1–3 as natural products, discarding the p
This journal is © The Royal Society of Chemistry 2017actually biosynthesized by the organism or is it an artefact of the
extraction, fractionation and/or the purication processes?
Indeed, this question is of particular relevance when isolating
compounds of extremely low yield, for instance those in the
baseline of a chromatographic run aer scaling up an extraction
process, and/or when isolating compounds that represent
minor derivatives of known compounds, for example methyl
esters or close related biosynthetic precursors. This project
encompasses all of those aspects. We isolated compounds 2 and
3 as minor side fractions when targeting the large-scale devel-
opment of compound 4. Moreover, the analogues, while struc-
turally interesting, particularly from a biosynthetic standpoint,
represent minor deviations of well-known compounds, in this
case the lack of two amino acid residues in 2 or the presence of
a glutamic acid methyl ester in 3.
Thus, the possibility of isolation of compound 3 as an arte-
fact was discarded based on the outcomes obtained from two
experiments. First, alamethicin F50 (4), the compound isolated
in high yield from the extract of MSX70741, was stored in MeOH
for one month at room temperature. Aerwards, the 1H-NMR
spectrum was recorded, and the presence of the –OMe singlet
at dH 3.27 was not observed (data not shown). In addition, in situ
UPLC-UV/HRESIMS-MS/MS analysis of the culture of strainwn in PDA using a droplet-liquid microjunction-surface sampling probe
S-MS/MS). (A) Base peak extracted chromatograms for compounds 1
p), 2 (middle), and 3 (bottom). (C) Base peak chromatogram of the in situ
n chromatograms (XIC) ofm/z 920.57 (1; maroon),m/z 513.30 (2, green)
) Full-scan MS at 5.78 (top) and 6.95 min (bottom). Extracted HRESIMS at
n for compounds 2 (top; in source fragments boxed in green), 1 (bottom,
boxed in blue) within5.0 ppm. Application of this methodology allowed
ossibility of artifacts of the isolation process.
RSC Adv., 2017, 7, 45733–45741 | 45737
Table 2 Cytotoxic activity of compounds 1, 3, 4 and 6 against a panel
of cancer cell linesa
Compounds
IC50 values (mM)
HCT-116 DLD-1 HT-29 SW948 HepG2 Huh-7 HeLa
1 6.8 >8 6.7 >8 >8 >8 >8
3 2.6 6.1 3.2 4.0 6.5 3.0 2.5
4 3.2 NT NT NT NT 6.5 5.7
6 3.5 4.7 3.7 4.0 6.3 4.0 3.0
a NT: not tested.
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View Article OnlineMSX70741 grown in potato-dextrose-agar (PDA) for 21 days,
using a droplet-LMJ-SSP,18,20 was used to validate the authen-
ticity of 3 as a true secondary metabolite. The results obtained
from this analysis showed a peak matching the retention time
and characteristic in-source ion peaks for compound 3, espe-
cially the fragment b13
+ and y7
+ at m/z 1189.69 and 789.45,
respectively, along with the [M + 2H]2+ ion at m/z 989.57 (Fig. 5).
Similar results were obtained for compounds 1 and 2, validating
the authenticity of all the new compounds (1–3) as true fungal
metabolites.Cytotoxic activity
The activity of compounds 1, 3, 4 and 6, were evaluated against
a panel of cancer cell lines, including strains HCT 116 (colo-
rectal carcinoma), DLD-1, HT-29, and SW948 (colorectal
adenocarcinomas), Hep-G2, and Huh-7 (hepatocellular carci-
nomas), and HeLa (adenocarcinoma),30 using an MTT assay
(Table 2). Compound 1 exhibited moderate activity against
strains HCT 116 and HT-29 with IC50 values of 6.8 and 6.7 mM,
respectively, and no activity against hepatocellular carcinomas
and adenocarcinoma cell lines. Glu(OMe)18-alamethicin F50 (3)
was the most active compound, with IC50 values ranging from
2.5 through 6.5 mM, and no selectivity against different cell lines
(Table 2). The bioactivity results of these compounds correlates
with their hydrophobicity and are in harmony with the ndings
previously reported for peptaibols biosynthesized from 11
amino acids39 and alamethicin F50 derivatives.10Experimental section
General experimental procedures
NMR experiments were conducted in DMSO-d6 or MeOH-d3
with presaturation of the OH peak at dH 4.92 ppm (wet experi-
ment). NMR instrumentation was an Agilent 700 MHz NMR
spectrometer (Agilent Technologies, Inc., Santa Clara, CA, USA)
equipped with a cryoprobe, operating at 700 MHz for 1H and
175 MHz for 13C. HRESIMS data were obtained using a Thermo
QExactive Plus mass spectrometer (ThermoFisher, San Jose, CA,
USA) combined with an electrospray ionization source. Der-
eplication of the fungal culture by in situ sampling was per-
formed using the droplet-LMJ-SSP coupled with a Waters
Acquity ultraperformance liquid chromatography (UPLC)
system (Waters Corp.) to a Thermo QExactive Plus.45738 | RSC Adv., 2017, 7, 45733–45741The droplet-LMJ-SSP experiments were carried out using
procedures described previously by Sica et al.18 Briey, extrac-
tions were performed using Fisher Optima LC/MS grade
solvents consisting of 25 : 25 : 50 MeOH–Dioxane–H2O. An
initial 5 mL of solvent were drawn into the syringe. Droplets of
4 mL were dispensed onto the surface of the sample at a rate of
2 mL s1, held on the surface for 2 s, and withdrawn back into
the syringe at the same rate. This extraction process was
repeated in triplicate for a single spot prior to injection into the
UPLC-MS system. The HCD fragmentation used a normalized
collision energy of 35 for all the compounds to obtain MS/MS
data. The UPLC separations were performed using an Acquity
BEH C18 column (50 mm  2.1 mm, internal diameter, 1.7 mm)
equilibrated at 40 C and a ow rate set at 0.3 mL min1. The
mobile phase consisted of a linear MeCN–H2O (acidied with
0.1% formic acid) gradient starting at 15% MeCN to 100%
MeCN over 8 min. The mobile phase was held for another
1.5 min at 100% MeCN before returning to the starting condi-
tions. The HPLC separations were performed using a Varian
ProStar HPLC system connected to a ProStar 335 photodiode
array detector (PDA) with UV detection set at 195 nm and
210 nm. Preparative HPLC purication of isolated compounds
was performed on a Phenomenex Synergi 4 mm particle size C12
column (21  250 mm) at a ow rate of 15.0 or 20.0 mL min1.
Semipreparative HPLC was carried out on a Phenomenex
Gemini-NX 5 mm particle size C18 column (10  250 mm) or
Phenomenex Synergi 4 mm particle size C12 column (10 
250 mm) at 4.6 mL min1. Flash column chromatography was
carried out with a Teledyne ISCO Combiash Rf connected to an
ELSD, and with UV detection set at 200–400 nm according with
established protocols.10,20,26,28,31,40
Fungal strain identication
Fungal strain identication was carried out following the
procedures outlined in detail previously.41 Also, the ESI† from
Rivera-Chávez et al., 2017,22 has specic details on the identi-
cation of this strain.
Fermentation, extraction and isolation
The MSX70741 strain (Trichoderma arundinaceum) was isolated
in April 1993 by Dr Barry Katz from wood collected in a humid
mountain forest (April 1993).10 A seed culture of the fungal
strain MSX70741 was grown on a malt extract agar slant, and
a small piece of agar with mycelium was transferred into YESD
media (followed by incubation for 7 days at 22 C with agitation
at 125 rpm). The seed culture was subsequently transferred into
a 2.8 L Fernbach ask containing 150 g of rice and 300 mL of
H2O to which was added a vitamin solution. Each ask was
incubated at 22 C until the cultures showed good growth. To
the large scale solid fermentation (4) of MSX70741 was added
500 mL of 1 : 1 CHCl3–MeOH, and the mixtures were shaken for
16 h at 100 rpm in a reciprocating shaker separately. The
solution was ltered, and equal volumes of H2O and CHCl3 were
added to a nal volume of 2 L, the mixture was stirred for 2 h
and then transferred into a separatory funnel. The bottom layer
was drawn off and evaporated to dryness. The extract wasThis journal is © The Royal Society of Chemistry 2017
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View Article Onlinedefatted by partitioning between 300 mL of a mixture of 1 : 1
MeOH–MeCN and 300 mL of hexane in a separatory funnel. The
bottom layer was collected and evaporated to dryness. The defatted
large scale extract (7.5 g) was adsorbed onto a minimal amount of
Celite 545 (Acros Organics) and mixed using mortar and pestle.
Thismaterial was fractionated via ash chromatography on a 120 g
RediSep Rf Gold Si-gel column, using a gradient solvent system of
hexane–CHCl3–MeOH at 85 mL min
1
ow rate and 30 column
volumes (CV) over 67.7 min, to afford ve fractions (F1–F5). Frac-
tion F5 (2.8 g), eluted with 100% MeOH, was subjected to reverse
phase ash chromatography on a 130 g C18 RediSep column using
a gradient solvent system of MeOH–H2O 20 : 80/ 100 : 0 over 20
CV and hold at 100 : 0 for 5 CV at 85 mLmin1 ow rate (a total of
25.0 CV over 38.2 min), to afford seven fractions (F5I–F5VII). Part of
fraction F5V (250 mg) was subjected to preparative HPLC using
a gradient system initiated with 40 : 60 MeCN–H2O (0.1% formic
acid) to 100%MeCN over 30min at a ow rate of 15.0mLmin1 to
generate 16 fractions (F5V1–16). Resolution of fraction F5V-4 by
semipreparative HPLC (Gemini-NX) using an isocratic system of
60 : 40 MeCN–H2O (0.1% formic acid) at 4.6 mL min
1 afforded
compound 7 (3.1mg, tR 14.5min) and compound 4 (2.0mg, tR 17.0
min). Fraction F5V-7 was resolved by semipreparative HPLC (Syn-
ergi) using an isocraticmethod of 60 : 40MeCN–H2O (0.1% formic
acid) to afford compound 2 (4.3 mg, tR 14.0 min). Resolution of
fraction F5V-8 using an isocratic method of 60 : 40 MeCN–H2O
(0.1% formic acid) led to the isolation of 3 (4.0 mg, tR 17.5–20.0
min). Fractions F5I, and F5II were combined and fractionated by
preparative HPLC using a gradient system initiated with 40 : 60
MeCN–H2O (0.1% formic acid) to 100% MeCN over 30 min at
a ow rate of 15.0mLmin1 to generate 10 fractions. Resolution of
fraction F5I–II-3 using a gradient method starting at 40 : 60 MeCN–
H2O (0.1% formic acid) to 100%MeCN over 30min at a ow rate of
4.6 mLmin1 in a Synergi column led to the isolation of 1 (1.2 mg,
tR 17.5–20.0 min). Compounds 5 and 6 were obtained from frac-
tions F5V-6 and F5I–II, respectively (5, 50.4 mg; 6, 13.5 mg),
approximately 130 mg more of compound 4 were isolated readily
from different fractions.
Trichobrenin BIII-D (1). White powder; [a]27D ¼ 3.0 (c ¼
0.20, MeOH); UV (MeOH) lmax (log 3) 211 (3.75) nm;
1H NMR
(DMSO-d6, 700 MHz) and
13C NMR (DMSO-d6, 175 MHz), see
Table 1; HRESIMS m/z 1134.7506 [M + H]+; calc. for
C56H100N11O13 1134.7496.
Prealamethicin F50 (2).White powder; [a]27D ¼1.0 (c¼ 0.10,
MeOH); UV (MeOH) lmax (log 3) 212 (4.25) nm;
1H NMR (MeOH-
d3, 700 MHz) and
13C NMR (MeOH-d3, 175 MHz), see Table S1;†
HRESIMS m/z 1701.9910 [M + H]+; calc. for C78H132N20O22
1701.9897.
Glu(OMe)18-alamethicin F50 (3). White powder; [a]27D ¼ 6.0
(c ¼ 0.27, MeOH); UV (MeOH) lmax (log 3) 212 (3.89) nm; 1H
NMR (DMSO-d6, 700 MHz) and
13C NMR (DMSO-d6, 175 MHz),
see Table S1;† HRESIMS m/z 1978.1337 [M + H]+; calc. for
C93H153N22O25, m/z 1978.1371.Marfey's analysis
This was carried out as described in detail previously.10,19,22
Briey, approximately 0.2 mg of each amino acid standard wasThis journal is © The Royal Society of Chemistry 2017weighed into 2 mL reaction vials. To each standard was added
50 mL of H2O, 20 mL of 1 M NaHCO3, and 100 mL 1% Marfey's
reagent (Na-(2,4-dinitro-5-uorophenyl)-L-alaninamide, Acros
Organics) in acetone. The reaction mixtures were agitated at
40 C for 1 h. The reactions were stopped by adding 10 mL of 2 N
HCl. The product of the reactions was dried under a stream of
N2 and dissolved in 1.7 mL of MeOH. Each derivatized stan-
dard was injected individually (1.0 mL) onto the UPLC. The
UPLC conditions were 10–70% MeOH in 0.1% of formic acid in
water over 10 min on a BEH C18 column, and the eluent was
monitored at 340 nm.
The digested and derivatized peptaibols were generated
using the following procedure: approximately 0.2–0.3 mg of
compounds 1–3 were weighed separately into 2 mL reaction
vials, to which was added 0.5 mL of 6 N HCl. The compounds
were hydrolyzed at 90 C for 24 h, and then evaporated under
a stream of N2. To each hydrolysis product was then added
25 mL H2O, 10 mL 1 M NaHCO3, and 50 mL of 1% Marfey's
reagent in acetone. The reaction mixtures were agitated at 40 C
for 1 h. The reactions were halted by the addition of 5 mL of 2 N
HCl. The mixtures were dried under a stream of N2 and brought
up in 200 mL of MeOH and injected onto the UPLC using the
same conditions as for the standards.Cytotoxicity assay
Cell culture. Cell-culture reagents, antibiotics and other
supplements were purchased from Sigma, USA. Fetal Bovine
Serum (FBS, US certied) was from Invitrogen Life Sciences,
USA. HCT-116, DLD-1, HT29, SW948, HepG2, Huh-7, HeLa cells
were grown in Dulbecco's Modied Eagle's Medium (Sigma-
Aldrich, USA) or RPMI-1640 (with 10% FBS, 100 units/mL
penicillin and 100 mg mL1 streptomycin) (Invitrogen Life
Sciences, USA). The cells were maintained at 37 C in a humid-
ied atmosphere with 5% CO2. All cell-culture work was per-
formed under aseptic conditions inside a laminar airow
chamber.
Assay. Toxicity of the compounds in different cell lines in the
presence of 0.2% FBS was determined using 3-(4,5-
dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide reduc-
tion assay (MTT assay). Compounds were dissolved in DMSO at
10 mg mL1 concentration and stored at 20 C. The dilutions
were made in culture medium before treatment. 5  103 cells
per well was plated in a 96-well plate. Aer 24 h of plating, the
cells were treated with different concentrations of compounds
in triplicates. MTT (20 mL of 5 mg mL1) was added to the cells
aer 44 h. The medium was removed from the wells 4 h aer
MTT addition. 200 mL of DMSO were added to dissolve the
formazan crystals, and the absorbance was then measured at
570 nm in an enzyme-linked immunosorbent assay reader.
Alamethicin F50 (4) was used as a positive control, as it has been
tested extensively in the literature.10,22Conclusions
In conclusion, three new peptaibols (1–3) were isolated and
characterized from the organic extract of the fungusRSC Adv., 2017, 7, 45733–45741 | 45739
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View Article OnlineTrichoderma arundinaceum (strain MSX70741). The structures of
the isolates were established using high eld 1D and 2D NMR
(700 MHz) and spectrometric (HRESIMS/MSn) techniques, and
their absolute conguration determined by Marfey's analysis of
the individual amino acids using a 10 min UPLC method.
Compound 3 represents the second report of peptaibols con-
taining a d-methyl ester of glutamic acid. Compounds 1, 3, 4
and 6 were evaluated for their cytotoxicity against a panel of
cancer cell lines. Products 3 and 6 displayed promising activity
with IC50 values in the lower micromolar range. Importantly,
in situ UPLC-UV/HRESIMS-MS/MS analysis of the culture of
strain MSX70741 grown in potato-dextrose-agar allowed the
identication of compounds 2–3 as natural products, elimi-
nating the possibility of artefacts of the isolation process. This
study added another application of the droplet-LMJ-SSP, con-
rming it as a powerful and effective tool to address some of the
common problems and questions in natural products research
and drug discovery, such as those regarding the biosynthesis of
targeted compounds, chemical ecology (spatial distribution of
metabolites) and improving the efficacy of protocols focused on
the discovery of new drug leads from nature (dereplication
protocols). Finally, this study highlights the benet of scaling
up the fermentation conditions of a targeted microorganism, as
doing so oen present opportunities to uncover new chemical
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J. Cole, Q. Wang, P. Crous, V. Robert, T. Helgason,
J. R. Herr, P. Kirk, S. Lueschow, K. O'Donnell,
R. H. Nilsson, R. Oono, C. Schoch, C. Smyth, D. M. Walker,
A. Porras-Alfaro, J. W. Taylor and D. M. Geiser, Mycologia,
2016, 108, 1049–1068.
6 F. Almassi, E. L. Ghisalberti, M. J. Narbey and
K. Sivasithamparam, J. Nat. Prod., 1991, 54, 396–402.
7 P. K. Mukherjee, B. A. Horwitz and C. M. Kenerley,
Microbiology, 2012, 158, 35–45.
8 J. L. Reino, R. F. Guerrero, R. Hernández-Galán and
I. G. Collado, Phytochem. Rev., 2008, 7, 89–123.
9 N. K. N. Neumann, N. Stoppacher, S. Zeilinger, T. Degenkolb,
H. Brückner and R. Schuhmacher, Chem. Biodiversity, 2015,
12, 743–751.
10 S. Ayers, B. M. Ehrmann, A. F. Adcock, D. J. Kroll,
E. J. Carcache de Blanco, Q. Shen, S. M. Swanson,
J. O. Falkinham, M. C. Wani, S. M. Mitchell, C. J. Pearce
and N. H. Oberlies, J. Pept. Sci., 2012, 18, 500–510.
11 T. Degenkolb, A. Berg, W. Gams, B. Schlegel and U. Gräfe, J.
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